Agent for preventing, treating, or improving inflammatory skin disease

Abstract

To provide an agent for preventing, treating, or improving inflammatory skin disease.SOLUTION: An agent for preventing, treating, or improving inflammatory skin disease includes, as an active ingredient, oils and fats in which the content of α-linolenic acid is 40 mass% or more and the content of diacylglycerol is 25 mass% or more in the fatty acids constituting the oils and fats.SELECTED DRAWING: None

Description

Technical Field

[0001] The present invention relates to a prophylactic, therapeutic or ameliorating agent for inflammatory skin diseases such as atopic dermatitis.

Background Art

[0002] Atopic dermatitis (AD) is one of the skin diseases accompanied by inflammation, and is a disease caused by genetic factors and environmental factors. Recent research has revealed that the pathogenesis of atopic dermatitis involves both immunological abnormalities and a deficiency in the skin barrier function. The skin barrier function is mainly borne by the stratum corneum and the sebum film covering its surface, and by their normal functioning, it prevents water loss from the body and the invasion of various stimuli and substances from the outside. However, in atopic dry skin, which is often seen in patients with atopic dermatitis, the skin barrier function fails, and the invasion of environmental allergens and stimuli, the onset, exacerbation, and induction of itching of eczema act in a vicious cycle, causing the chronicization and intractability of the disease state. The abnormality of the skin barrier function is also prominent in patients with psoriasis vulgaris and other similar skin conditions. Therefore, in the treatment of atopic dermatitis and the like, it is important to lead to a remission state by suppressing inflammation and normalizing the skin barrier function.

[0003] α-Linolenic acid (C18:3, ALA) is a highly unsaturated fatty acid of the ω3 series that is abundant in flaxseed oil and perilla seed oil. It has been reported that α-linolenic acid has anti-atherosclerotic, antihypertensive, anti-allergic effects, etc. Also, it has been reported that the intake of flaxseed oil improves the value of transepidermal water loss (TEWL) in dry and sensitive skin (Non-Patent Document 1). On the other hand, oils and fats containing a high concentration of diacylglycerol have a low postprandial blood triglyceride (neutral It has been reported to have physiological effects such as suppressing the increase of fat and having low accumulation in the body. For example, Patent Document 1 states that 15 to 90% by weight of the constituent fatty acids are ω3 with fewer than 20 carbon atoms. It is a polyunsaturated fatty acid, cis-ω3 polyunsaturated fatty acid / (cis-ω6 polyunsaturated fatty acid + saturated Diglycerides with a weight ratio of fatty acids + trans unsaturated fatty acids of 1-6 are used in 60-100 units. It has been reported that oil and fat compositions containing this ingredient by weight have excellent properties for burning visceral fat and body fat. It has been reported. However, it contains diacylglycerol, which is rich in alpha-linolenic acid as a constituent fatty acid. It is known that oils and fats are useful in preventing or treating inflammatory skin diseases such as atopic dermatitis. not present. [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] Japanese Patent Publication No. 2002-138296 [Non-patent literature]

[0005] [Non-Patent Document 1] Jean-Marc Maurette. OCL. 2008, 15(4), 257-261 [Overview of the project] [Problems that the invention aims to solve]

[0006] This invention relates to providing an agent for the prevention, treatment, or improvement of inflammatory skin diseases. [Means for solving the problem]

[0007] The inventors used a mouse model of atopic dermatitis to find a diamine rich in alpha-linolenic acid. As a result of evaluating the effectiveness of the oil containing sylglycerol, in mice fed with a diet supplemented with a diacyl glycerol-containing oil rich in α-linolenic acid, the dermatitis score and ear swelling were suppressed, the increase in transepidermal water loss (TEWL) was suppressed, and the increase in various cytokines related to inflammatory skin diseases was suppressed. It was found that the oil is useful for the prevention or treatment of inflammatory skin diseases such as atopic dermatitis.

[0008] That is, the present invention relates to the following 1) to 4). 1) A preventive, therapeutic or ameliorating agent for inflammatory skin diseases, comprising as an active ingredient an oil in which the content of α-linolenic acid in the fatty acids constituting the oil is 40% by mass or more and the content of diacylglycerol is 25% by mass or more. 2) An agent for improving skin barrier function, comprising as an active ingredient an oil in which the content of α-linolenic acid in the fatty acids constituting the oil is 40% by mass or more and the content of diacyl glycerol is 25% by mass or more. 3) A food for preventing or ameliorating inflammatory skin diseases, comprising as an active ingredient an oil in which the content of α-linolenic acid in the fatty acids constituting the oil is 40% by mass or more and the content of diacylglycerol is 25% by mass or more. 4) A food for improving skin barrier function, comprising as an active ingredient an oil in which the content of α-linolenic acid in the fatty acids constituting the oil is 40% by mass or more and the content of diacyl glycerol is 25% by mass or more.

Effects of the Invention

[0009] According to the present invention, pharmaceuticals, foods, etc. effective for the prevention, treatment or amelioration of inflammatory skin diseases are provided by suppressing dermatitis and improving skin barrier function.

Brief Description of the Drawings

[0010] [Figure 1] A graph showing changes in the Dermatitis Score (AD). [Figure 2] A graph showing changes in the thickness of the auricle. [Figure 3] A graph showing the change in transepidermal water loss (TEWL). [Figure 4] A graph showing the results of cytokine expression analysis at the site of dermatitis induction. [Modes for carrying out the invention]

[0011] In this invention, "oils and fats" refers to ester compounds of fatty acids and glycerol, and mono- One of the following: silglycerol, diacylglycerol, and triacylglycerol This includes the above. There are no particular restrictions on the type of oil or fat; it can be used as an edible oil or fat. Any of them is fine.

[0012] The oils and fats used in this invention have an α-linolenic acid content of 40% by mass in the fatty acids that make up the oils and fats. This refers to oils and fats that are % or more in content and have a diacylglycerol content of 25% by mass or more. In this specification, "the content of α-linolenic acid in the fatty acids constituting the oil is 40% by mass or less" The term "oils and fats that are above and have a diacylglycerol content of 25% by mass or more" is simply "Invention It is sometimes written as "oils and fats."

[0013] The α-linolenic acid content in the fatty acids constituting the oil and fat of the present invention is 40% by mass or more. From the viewpoint of physiological effects, preferably 45% by mass or more, more preferably 50% by mass or more, and further Preferably 52% by mass or more, and from the viewpoint of oxidation stability, preferably 80% by mass or less. More preferably, it is 70% by mass or less, and even more preferably 60% by mass or less. The alpha-linolenic acid content in the fatty acids that make up the oils and fats is between 40% and 80% by mass. Preferably 45% by mass or more and 80% by mass or less, more preferably 50% by mass or more and 80% by mass More preferably, 50% by mass or more and 70% by mass or less, and even more preferably 52% by mass or more and 7% by mass or less The amount is 0% by mass or less, more preferably 52% by mass or more and 60% by mass or less. The amount of fatty acids is expressed in terms of free fatty acid equivalents.

[0014] In the present invention, the constituent fatty acids other than α-linolenic acid that constitute the oil and fat are not particularly limited. It is not necessary, and either saturated or unsaturated fatty acids may be used. From the perspective of the flavor and industrial productivity of oils and fats, the content of unsaturated fatty acids in the fatty acids that make up oils and fats is important. The amount is preferably 60% by mass or more and 100% by mass or less, more preferably 70% by mass or more and 10% by mass or less. 0% by mass or less, more preferably 75% by mass or more and 99% by mass or less, and even more preferably 80% by mass The amount is between % and 98% by mass. From the viewpoint of physiological effects, the number of carbon atoms in the unsaturated fatty acid is preferably 14-24, more preferably 16-22.

[0015] The amount of linoleic acid (C18:2) in the fatty acids that make up oils and fats is important from the perspective of industrial productivity. Preferably, it is 5% by mass or more, more preferably 10% by mass or more, and also, physiological effects From that point, preferably 40% by mass or less, more preferably 30% by mass or less, and even more preferably 2% by mass or less. It is 0% by mass or less. The content of linoleic acid (C18:2) in the fatty acids that make up the oil and fat is preferably 5% by mass. The above is 40% by mass or less, more preferably 10% by mass or more and 30% by mass or less, even more preferably The amount is between 10% by mass and 20% by mass.

[0016] Furthermore, the oleic acid (C18:1) content in the fatty acids that make up oils and fats is related to industrial productivity. From this point of view, it is preferably 10% by mass or more, and from the point of physiological effect, it is preferably 50 It is less than or equal to mass%, more preferably 40% by mass or less, and even more preferably 30% by mass or less. The content of oleic acid (C18:1) in the fatty acids that make up the oil and fat is preferably 10 by mass. % to 50% by mass, more preferably 10% to 40% by mass, even more preferably Alternatively, it is between 10% by mass and 30% by mass.

[0017] The total saturated fatty acid content in the fatty acids that make up oils and fats is important for appearance, physiological effects, and the industrial use of oils and fats. From the standpoint of productivity, preferably 6.0% by mass or less, more preferably 5.5% by mass or less, and further Preferably, it is 5.0% by mass or less. Also, from the viewpoint of industrial productivity, it is preferably 0.5%. It is greater than or equal to mass%. The total content of saturated fatty acids in the fatty acids constituting the oil and fat is preferably 0.5% by mass or more. 0% by mass or less, more preferably 0.5% by mass or more and 5.5% by mass or less, even more preferably 0 It is between 0.5% by mass and 5.0% by mass. The type of saturated fatty acid is not particularly limited, but preferably saturated fatty acids with 14 to 24 carbon atoms. More preferably saturated fatty acids having 16 to 22 carbon atoms, even more preferably 16, 18, or 20 carbon atoms. It is a saturated fatty acid.

[0018] The diacylglycerol content in the oil and fat of the present invention is 25% by mass or more, but the effect is From the standpoint of efficacy and physiological effects, preferably 30% by mass or more, more preferably 50% by mass. Amount % or more, more preferably 55% by mass or more, more preferably 60% by mass or more, even more preferably The amount is 65% by mass or more, more preferably 70% by mass or more, and even more preferably 80% by mass or more. More preferably 83% by mass or more, even more preferably 84% by mass or more, and also preferably It is 96% by mass or less, more preferably 95% by mass or less, and even more preferably 94% by mass or less. ru. The diacylglycerol content in the oil is preferably 25% by mass or more and 96% by mass or less. More preferably 30% by mass or more and 96% by mass or less, even more preferably 50% by mass or more and 96% by mass Amount % or less, more preferably 50% by mass or more and 95% by mass or less, even more preferably 55% by mass or less Up to 95% by mass, more preferably 60% by mass or more and 95% by mass or less, even more preferably 65% Mass% or more and 95% or less by mass, more preferably 65% ​​or more and 94% or less by mass, even more preferably More preferably 70% by mass or more and 94% by mass or less, more preferably 80% by mass or more and 94% by mass or less, Preferably 83% by mass or more and 94% by mass or less, more preferably 84% by mass or more and 94% by mass The following applies:

[0019] In this invention, the fatty acids constituting diacylglycerol are saturated fatty acids or unsaturated fatty acids. Any acid may be used, but α-linolene in the fatty acids that make up diacylglycerol A higher acid content of 40% by mass is preferable for the effect to be effectively expressed. The amount of alpha-linolenic acid in the fatty acids that make up diacylglycerol is similar to the above. Preferably 45% by mass or more, more preferably 50% by mass or more, and even more preferably 52% by mass It should be % or more, and from the viewpoint of oxidation stability, preferably 80% by mass or less, more preferably The amount is 70% by mass or less, more preferably 60% by mass or less. The alpha-linolenic acid content in the fatty acids constituting diacylglycerol is 40% by mass or less. Up to 80% by mass, preferably 45% to 80% by mass, more preferably 50% by mass % or more and 80% by mass or less, more preferably 50% by mass or more and 70% by mass or less, even more preferably The amount is 52% by mass or more and 70% by mass or less, more preferably 52% by mass or more and 60% by mass or less.

[0020] The oils and fats of the present invention may contain triacylglycerol, and the amount thereof is... From the viewpoint of industrial productivity, preferably 1% by mass or more, more preferably 2% by mass or more, and further Preferably 5% by mass or more, preferably 75% by mass or less, more preferably 72% by mass. The amount is less than or equal to mass%, more preferably 50% by mass or less, and more preferably 25% by mass or less. The triacylglycerol content in the oil is preferably 1% by mass or more and 75% by mass or less. More preferably 2% by mass or more and 75% by mass or less, and even more preferably 2% by mass or more and 72% by mass More preferably, 5% by mass or more and 72% by mass or less, and even more preferably 5% by mass or more and 50% by mass. The amount is less than or equal to % by mass, and more preferably 5% by mass or more and 25% by mass or less. Furthermore, the monoacylglycerol content in oils and fats is important in terms of flavor and the industrial productivity of oils and fats. Preferably, it is 3% by mass or less, more preferably 2% by mass or less, and even more preferably 1%. The amount is 51% by mass or less, and preferably more than 0% by mass. Monoacylglycerides in fats and oils The roll content may be 0% by mass. Triacylglycerols, diacylglycerols, and monoacylglycerols Having the same composition is preferable in terms of the industrial productivity of oils and fats.

[0021] The oils and fats of the present invention may contain free fatty acids or salts thereof as impurities. The content of free fatty acids or their salts is preferably 3% by mass or less, more preferably from the viewpoint of flavor. It is 2% by mass or less, more preferably 1% by mass or less, and preferably more than 0% by mass. Yes. The content of free fatty acids or their salts in the oil may be 0% by mass.

[0022] The oils and fats of the present invention are obtained by esterification reaction of fatty acids derived from oils and fats with glycerol according to a conventional method. It can be obtained by transesterification (glycerolysis) of oils and fats and glycerin. Regular edible oils and fats may be added as needed. Esterification reactions and glycerol-lysis reactions occur with alkali metals or their alloys, alkali metals or These are oxides and hydroxides of alkaline earth metals, alkali metals or alkaline earth metals. These methods are broadly classified into chemical methods using chemical catalysts such as sides, and enzymatic methods using enzymes such as lipases. In particular, from the standpoint of controlling the fatty acid composition, fatty acids obtained by hydrolyzing oils and fats, as described later, are important. Esterification reaction between (fractionated fatty acids) and glycerol is preferred.

[0023] In this invention, the origin of the oil or fat is not particularly limited as long as it can be used as an edible oil or fat. It can be either vegetable oil or animal oil. For example, soybean oil, rapeseed oil, safflower oil. Rice oil, corn oil, sunflower oil, cottonseed oil, olive oil, sesame oil, peanut oil, Job's tears oil, Wheat germ oil, perilla oil, linseed oil, egoma oil, chia seed oil, sacha inchi oil, walnut oil, Kiwi seed oil, sage seed oil, grape seed oil, macadamia nut oil, hazelnut oil Pumpkin seed oil, camellia oil, tea seed oil, borage oil, palm oil, palm olein, palm stem Vegetable oils such as allin, coconut oil, palm kernel oil, cocoa butter, sal butter, shea butter, and algae oil; fish oil, Animal fats and oils such as seal oil, lard, beef tallow, butter fat, etc.; or transesterified oils thereof. Examples include oils and fats such as hydrogenated oils and fractionated oils. These oils may be used individually or mixed together as appropriate. However, from the standpoint of usability, it is preferable to use vegetable oils, and even more preferably a liquid with excellent low-temperature tolerance. It is preferable to use oils and fats, and further, to select from the group consisting of perilla oil, linseed oil, and egoma oil. Using one or more types of oils and fats is preferable because it is rich in alpha-linolenic acid. Liquid oils are defined as those that undergo a cooling test according to the standard oil analysis test method 2.3.8-27. This refers to oils and fats that are liquid at 20°C. Furthermore, edible oils and fats are refined oils and fats that have undergone a refining process. preferable.

[0024] Fatty acids derived from oils and fats can be obtained by hydrolyzing oils and fats. Methods for hydrolyzing oils and fats. Examples include high-temperature, high-pressure decomposition and enzymatic decomposition. High-temperature, high-pressure decomposition involves dissolving oils and fats in water. In addition, this method involves reacting fatty acids and glycerol under high temperature and high pressure conditions. Furthermore, enzymatic hydrolysis is a method in which water is added to oils and fats, and an oil hydrolase is used as a catalyst, at low temperatures. This method involves reacting fatty acids and glycerol under certain conditions. The hydrolysis reaction can be carried out according to conventional methods.

[0025] After hydrolysis of oils and fats, it is preferable to separate the hydrolysis reaction products and remove the solids. Methods include solvent fractionation, natural fractionation (dry fractionation), and wetting agent fractionation. Methods for removing precipitated solids include static separation, filtration, centrifugation, and aqueous solution of fatty acids with a wetting agent. Methods for mixing and separating the substances are examples of such methods.

[0026] The esterification reaction between fatty acids derived from oils and fats and glycerol is carried out under mild conditions using an enzymatic method. This is preferable because it is superior in terms of flavor and other factors. The amount of enzyme used can be determined appropriately considering the enzyme activity, but improving the reaction rate Therefore, when using immobilized enzymes, the amount of enzymes used is preferable to the total mass of the esterification reaction raw materials. The amount is 1 to 30% by mass, more preferably 2 to 20% by mass. The reaction temperature for esterification reactions is important because it improves the reaction rate and suppresses enzyme inactivation. Preferably 0 to 100°C, more preferably 20 to 80°C, and even more preferably 30 to 60°C. There is. Also, from the standpoint of industrial productivity, the reaction time is preferably within 15 hours, more preferably within 15 hours. More preferably, it is 1 to 12 hours, and more preferably 2 to 10 hours. As a means of contact between fatty acids and glycerol, immersion, stirring, and a method of filling with immobilized lipase are used. Methods include passing liquid through the ram using a pump or similar device.

[0027] After the esterification reaction, a refining process, which is normally used for oils and fats, may be carried out. These processes include distillation, acid treatment, washing, decolorization, and deodorization.

[0028] As shown in the examples below, when the oils and fats of the present invention are administered to atopic dermatitis model mice, Furthermore, the dermatitis score, which represents the degree of progression of atopic dermatitis, and the thickening of the auricle were suppressed, and also, The increase in transepidermal water loss (TEWL) was suppressed. In addition, in the skin of the dermatitis-inducing site mRNA expression analysis revealed that in the group that ingested the lipids of the present invention, the major Th2 enzymes IL-4 is an itokine, and cytokarinocytes are secreted from innate immune cells and keratinocytes. The increased expression of the enzymes IL-1β, IL-6, TSLP, and IL-33 was suppressed. The cytokines whose expression is suppressed by the lipids of the present invention are used in atopic dermatitis. In addition, various inflammations such as seborrheic dermatitis, contact dermatitis, psoriasis, xerotic eczema, and erythema nodosum. It has been reported to contribute to inflammatory responses and impaired barrier function in symptomatic skin diseases. (Reference; Adalsteinsson JA, Kaushik S, et al. Exp Dermatol. 2020 May;29(5):48 1-489, Lee HY, et al. Mediators Inflamm. 2013;2013:916497, Belge K, et al. F1000 Prime Rep. 2014 Jan 2;6:4, Hanel KH, et al. Int J Mol Sci. 2013 Mar 26;14(4):672 0-45, Polycarpou A, et al. Front Immunol. 2017 Mar 13;8:233). Therefore, the present invention Oils and fats are used as agents for the prevention, treatment, or improvement of inflammatory skin diseases, and as agents for improving the skin barrier function (hereinafter referred to as "inflammation"). It may be used as a preventive, therapeutic, or ameliorative agent for inflammatory skin diseases, and for the prevention, treatment, or improvement of inflammatory skin diseases. It can be used for the treatment or improvement of skin barrier function, and also for inflammatory skin It can be used to manufacture agents for the prevention, treatment, or improvement of diseases. Here, "use" can be use on humans or non-human animals, and may be therapeutic use. It may also be used for non-therapeutic purposes. "Non-therapeutic" means that it does not involve medical procedures, i.e., human use. This does not include methods of surgery, treatment, or diagnosis, more specifically, a physician or medical professional or This does not include methods in which a person under the direction of a physician performs surgery, treatment, or diagnosis on a human being. It is a matter of will.

[0029] In this specification, examples of "inflammatory skin diseases" include atopic dermatitis, Seborrheic dermatitis, contact dermatitis, psoriasis, sebum deficiency eczema, erythema nodosum, neonatal acne / acne-like These include rashes, miliaria, folliculitis, infant eczema, and dry skin. In particular, atopic dermatitis It is suitable. Atopic dermatitis is characterized by itchy eczema that repeatedly worsens and remits. This refers to a chronic disease that follows a specific course.

[0030] "Skin barrier function" refers to the function of preventing moisture evaporation from within the skin and the ability to protect the skin from the outside environment. This refers to the function of preventing the entry of substances. In this invention, the evaporation of moisture from inside the skin is Suitable for improving the protective function (moisture permeability barrier function). By improving the skin barrier function, the skin Treatment or improvement of xerosis (sebum deficiency), seborrheic dermatitis, etc., caused by decreased rheumatic function is possible. It becomes Noh.

[0031] "Prevention" means preventing or delaying the onset of a disease or symptom in an individual, or the individual This refers to reducing the risk of developing a disease or symptom. "Improvement" means a rise in the disease, symptoms, or condition, or the prevention or delay of the worsening of the disease, symptoms, or condition. , or it refers to the reversal, prevention, or delay of the progression of a disease or symptom. Furthermore, "treatment" encompasses not only the complete cure of a disease but also the improvement of symptoms.

[0032] The present invention's agents for the prevention, treatment, or improvement of inflammatory skin diseases are themselves the preventive agents for inflammatory skin diseases. Pharmaceuticals, quasi-drugs, cosmetics, etc., for prevention, treatment, or improvement, for improving skin barrier function. It can be used as food or animal feed, or incorporated into pharmaceuticals, quasi-drugs, cosmetics, food, or animal feed. It can be used as a material or in a formulation.

[0033] The pharmaceutical product (including quasi-drugs, hereinafter the same) uses the oils and fats of the present invention to treat inflammatory skin diseases. It is included as an active ingredient for preventing, treating, or improving the skin barrier function. The drug may be pharmaceutically acceptable as necessary, provided that the function of the active ingredient is not lost. It may contain a carrier, or other active ingredients, pharmacological components, etc. Pharmaceuticals can be administered in any dosage form. For example, tablets (chewable tablets) Oral solid preparations such as tablets, capsules, granules, powders, and lozenges, and oral liquid preparations. Parenteral preparations such as oral liquid preparations including syrups, injections, suppositories, inhalants, transdermal preparations, and topical preparations. Examples of formulations include oral administration. The preferred form of administration is oral administration. The form varies depending on the intended use. The degree can be adjusted as desired. These various dosage forms of the formulation may, if necessary, be supplied with a pharmaceutically acceptable carrier, for example, an excipient. Forming agents, binders, fillers, disintegrants, surfactants, lubricants, dispersants, buffers, osmotic pressure regulators, pH adjuster, emulsifier, preservative, stabilizer, thickener, fluidity improver, flavoring agent, foaming agent Prepare the product according to the standard method by appropriately combining it with fragrances, coating agents, diluents, and other medicinal ingredients. It is possible.

[0034] This cosmetic product uses the oils and fats of the present invention to prevent or improve inflammatory skin diseases, thereby improving the skin barrier function. It contains as an active ingredient for improving function. Furthermore, the cosmetic product does not lose the function of the active ingredient. Unless otherwise permitted, the carrier or other active ingredients, medicinal properties permitted in cosmetics may be used as needed. It may contain ingredients, cosmetic ingredients, etc. Preferred examples of cosmetics containing oils and fats according to the present invention include cosmetics for the face and body (for example, ro (Lotteries, gels, creams, masks, etc.), makeup cosmetics, facial or body cleansers. Fees and other charges are listed. Each of these cosmetic formulations can be manufactured in accordance with conventional methods. In terms of composition, for example, various oils, surfactants, gelling agents, buffering agents, preservatives, antioxidants, Solvents, dispersants, chelating agents, thickeners, UV absorbers, emulsifying stabilizers, pH adjusters, colorants, fragrances Fees and other charges are listed. Other active ingredients, medicinal ingredients, and cosmetic ingredients include, for example, plant extracts, antiseptics, and moisturizers. Examples include anti-inflammatory agents, antibacterial agents, keratolytic agents, cooling agents, anti-seborrheic agents, cleansing agents, and makeup ingredients. It is possible.

[0035] This food product utilizes the oils and fats of the present invention to prevent or improve inflammatory skin diseases, thereby improving the skin barrier function. It contains this as an active ingredient for improving [the condition]. Foods may help prevent or improve symptoms seen in inflammatory skin diseases, or improve skin barrier function. Foods that promote health benefits and, if necessary, have permission or notification to display such claims (Foods for Specified Health Uses, This includes foods with functional claims and foods for special dietary uses. An example of a label is: "Helps retain moisture in the skin." These include features such as "it has a function to lift and alleviate dryness" and "it has a function to improve skin discomfort." Food products for which a special label has been approved or registered can be distinguished from ordinary food products. Food can be solid, semi-solid, or liquid (e.g., beverages). Examples include various foods. Product composition (bread, cakes, noodles, confectionery, frozen foods, ice cream, candy, etc.) (Seasonings, soups, dairy products, shakes, beverages, condiments, etc.), and also the oral administration mentioned above. Forms similar to pharmaceutical preparations (granules, powders, tablets, capsules, microcapsules, lozenges) Examples include nutritional supplement compositions in the form of solid preparations. Various forms of food may be used in this invention, including oils and fats, any food material, or other active ingredients. Food additives that are permitted (e.g., solvents, softeners, oils, emulsifiers, preservatives, acidulants, sweeteners) bittering agent, pH adjuster, stabilizer, coloring agent, UV absorber, antioxidant, humectant, thickener, Combine as appropriate with adhesives, dispersants, fluidity improvers, wetting agents, flavorings, seasonings, flavor modifiers, etc. It can then be prepared according to standard methods.

[0036] This feed contains the oils and fats of the present invention to prevent or improve inflammatory skin diseases, and to improve the skin barrier function. It contains this as an active ingredient for improving [the condition]. The feed is preferably in the form of pellets, flakes, mash, or liquid. For example, livestock feed used for cattle, pigs, chickens, sheep, horses, etc., and feed for rabbits, rats, mice, etc. Examples include small animal feed used for animals, and pet food used for dogs, cats, small birds, etc. The feed contains the oils and fats of the present invention, along with other feed materials such as meat, protein, grains, rice bran, and meal. Sugars, vegetables, vitamins, minerals, gelling agents, shape-retaining agents, pH adjusters, seasonings, preservatives It can be prepared according to standard methods by combining it with preservatives, nutritional supplements, etc., as appropriate.

[0037] The amount of the oil and fat of the present invention in the formulation varies depending on the form of the formulation, so it cannot be stated in general terms. For example, based on the total amount of the formulation, it is preferably 0.5% by mass or more, and also preferably It is 99.8% by mass or less.

[0038] The dosage or amount used of the oil or fat of the present invention may be an amount sufficient to achieve the effects of the present invention. The dosage or amount used will vary depending on the species, weight, sex, age, condition, or other factors. However, in the case of oral administration (ingestion), the oil of the present invention should be administered once per adult (60 kg). As fat, for example, it is between 0.3 and 15 grams. The above-mentioned preparations may be administered or used according to any dosing schedule, but may be taken once or multiple times a day. In separate cases, for 1 day or more, preferably 7 days or more, more preferably 14 days or more, and even further Preferably, it can be administered or used repeatedly and continuously for 30 days or more.

[0039] The present invention's preventive, therapeutic, or ameliorative agent for inflammatory skin diseases is administered in the form of an oil composition or It is preferable that it be used. When an agent for the prevention, treatment, or improvement of inflammatory skin diseases is in the form of an oil and fat composition, the oil and fat composition The oil content of the present invention is preferably 90% by mass or more, more preferably, from the viewpoint of usability. The mass content is 95% or more, preferably 100% or less, and more preferably 99%. It is 9% by mass or less.

[0040] Oil and fat compositions are preferably made to contain antioxidants from the viewpoint of flavor, oxidative stability, and discoloration suppression. The amount of antioxidants in the oil and fat composition is desirable in terms of flavor, oxidative stability, and discoloration suppression. More preferably 0.005% by mass or more and 1.0% by mass or less, and more preferably 0.04% by mass or more. The amount is 75% by mass or less, and more preferably 0.08% by mass or more and 0.5% by mass or less. As for antioxidants, there are no particular restrictions as long as they are used in food, but natural antioxidants, Citin, tocopherol, ascorbyl palmitate, ascorbyl stearate, jib Selected from butylhydroxytoluene (BHT) and butylhydroxyanisole (BHA), etc. It is preferable that at least one type is detected.

[0041] The subjects to whom the inflammatory skin disease prevention, treatment, or improvement agent of the present invention is administered or used are: For people who desire prevention, treatment, or improvement of inflammatory skin diseases, preferably atopic dermatitis, and skin Humans and other animals that desire improved barrier function are examples. Non-human animals include great apes and others. Examples include non-human mammals such as primates.

[0042] With regard to the embodiments described above, the present invention further discloses the following aspects.

[0043] <1> The alpha-linolenic acid content in the fatty acids that make up the oil is 40% by mass or more, Inflammatory skin disease treatment using oils and fats containing 25% or more by mass of silglycerol as an active ingredient A preventative, therapeutic, or ameliorative agent for [the condition].

[0044] <2> The alpha-linolenic acid content in the fatty acids that make up the oil is 40% by mass or more, Skin barrier function using oils and fats containing 25% or more by mass of silglycerol as an active ingredient. A corrective agent.

[0045] <3> The alpha-linolenic acid content in the fatty acids that make up the oil is 40% by mass or more, Inflammatory skin disease treatment using oils and fats containing 25% or more by mass of silglycerol as an active ingredient Food for the prevention or improvement of [condition].

[0046] <4> The alpha-linolenic acid content in the fatty acids that make up the oil is 40% by mass or more, Skin barrier function using oils and fats containing 25% or more by mass of silglycerol as an active ingredient. Food for improvement.

[0047] <5> Preferably, the α-linolenic acid content in the fatty acids constituting the oil is 45% by mass or more. More preferably 50% by mass or more, even more preferably 52% by mass or more, and also preferred The amount is 80% by mass or less, more preferably 70% by mass or less, and even more preferably 60% by mass or less. Yes, and also 40% by mass or more and 80% by mass or less, preferably 45% by mass or more and 80% by mass or less. More preferably 50% by mass or more and 80% by mass or less, more preferably 50% by mass or more and 70% by mass Amount % or less, more preferably 52% by mass or more and 70% by mass or less, even more preferably 52% by mass or less It is less than 60% by mass. <1> ~ <4> Any of the agents or foods described herein. <6> The content of linoleic acid (C18:2) in the fatty acids that make up the oil is preferably 5. It is % by amount or more, more preferably 10% by mass or more, and also preferably 40% by mass or less. Preferably 30% by mass or less, more preferably 20% by mass or less, and also preferably It is 5% by mass or more and 40% by mass or less, more preferably 10% by mass or more and 30% by mass or less, further Preferably, it is 10% by mass or more and 20% by mass or less. <1> ~ <5> The agent described in any of the following Or food. <7> The content of oleic acid (C18:1) in the fatty acids that make up the oil is preferably 10 It is 50% by mass or more, and more preferably 40% by mass or less. More preferably, it is 30% by mass or less, and more preferably 10% by mass or more and 50% by mass or less. More preferably 10% by mass or more and 40% by mass or less, and even more preferably 10% by mass or more. It is 30% by mass or less. <1> ~ <6> Any of the agents or foods described herein. <8> The diacylglycerol content in the oil is preferably 30% by mass or more, more preferably More preferably 50% by mass or more, more preferably 55% by mass or more, and even more preferably 60% by mass or more. More preferably 65% ​​by mass or more, even more preferably 70% by mass or more, even more preferably 80% It is % by mass or more, more preferably 83% by mass or more, and even more preferably 84% by mass or more. Preferably, 96% by mass or less, more preferably 95% by mass or less, and even more preferably 94% by mass. The amount is less than or equal to % and preferably 25% by mass or more and 96% by mass or less, more preferably 30% Mass% or more and 96% or less by mass, more preferably 50% or more and 96% or less by mass, even more preferably More preferably 50% by mass or more and 95% by mass or less, more preferably 55% by mass or more and 95% by mass or less, Preferably 60% by mass or more and 95% by mass or less, more preferably 65% ​​by mass or more and 95% by mass More preferably, 65% by mass or more and 94% by mass or less, and even more preferably 70% by mass or more. 4% by mass or less, more preferably 80% by mass or more and 94% by mass or less, even more preferably 83% by mass % to 94% by mass, more preferably 84% to 94% by mass. <1> The agent or food described in any of the items in <7>. <9> The amount of α-linolenic acid in the fatty acids constituting diacylglycerol is preferably is 40% by mass or more, more preferably 45% by mass or more, even more preferably 50% by mass or more, Preferably 52% by mass or more, more preferably 80% by mass or less, more preferably 70% by mass or less, more preferably 60% by mass or less, and also preferably 40% by mass or less More preferably 80% by mass or less, more preferably 45% by mass or more and 80% by mass or less, and even more preferably 50% Mass% or more and 80% or less by mass, more preferably 50% or more and 70% or less by mass, even more preferably The amount is 52% by mass or more and 70% by mass or less, more preferably 52% by mass or more and 60% by mass or less. ru <1> ~ <8> Any of the agents or foods described herein. <10> Inflammatory skin diseases are preferably atopic dermatitis, seborrheic dermatitis, and contact dermatitis. Psoriasis, asteatotic eczema, erythema nodosum, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema Rash or dry skin, more preferably atopic dermatitis, seborrheic dermatitis, or contact dermatitis. , psoriasis, xerotic eczema, or erythema nodosum, and more preferably atopic dermatitis be <1> , <3> , <5> ~ <9> Any of the agents or foods described herein. <11> The skin barrier function is preferably a water permeability barrier function. <2> , <4> , <5>~ <9> Any of the agents or foods described herein.

[0048] <12> Fats constituting oils and fats for the manufacture of agents for the prevention, treatment, or improvement of inflammatory skin diseases. The α-linolenic acid content in the acid is 40% by mass or more, and the diacylglycerol content is Uses oils and fats that make up 25% by mass or more. <13> Fatty acids that make up oils and fats, for use in the prevention, treatment, or improvement of inflammatory skin diseases. The alpha-linolenic acid content is 40% by mass or more, and the diacylglycerol content is Oils and fats that make up 25% or more by mass. <14> For the prevention, treatment, or improvement of inflammatory skin diseases, α in fatty acids that make up oils and fats - The linolenic acid content is 40% by mass or more, and the diacylglycerol content is 25% by mass Non-therapeutic use of oils and fats in amounts exceeding %. <15> Inflammatory skin diseases are preferably atopic dermatitis, seborrheic dermatitis, and contact dermatitis. Psoriasis, asteatotic eczema, erythema nodosum, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema Rash or dry skin, more preferably atopic dermatitis, seborrheic dermatitis, or contact dermatitis. , psoriasis, xerotic eczema, or erythema nodosum, and more preferably atopic dermatitis be <12> ~ <14> Oils or fats as described in any of the above.

[0049] <16> For the manufacture of a skin barrier function improving agent, α-linoleic acid in the fatty acids that make up oils and fats The acid content is 40% by mass or more, and the diacylglycerol content is 25% by mass or more. It uses oils and fats. <17> Alpha-linolenic acid in lipids for use in improving skin barrier function The acid content is 40% by mass or more, and the diacylglycerol content is 25% by mass or more. A certain type of fat or oil. <18> Alpha-linolenic acid, a fatty acid that makes up oils, to improve skin barrier function. The content is 40% by mass or more, and the diacylglycerol content is 25% by mass or more. Non-therapeutic use of oils and fats. <19> The skin barrier function is preferably a water permeability barrier function. <16> ~ <18> Oils or fats as described in any of the above. <20> The alpha-linolenic acid content in the fatty acids that make up diacylglycerol is 40 by mass. % or more <12> ~ <19> Oils or fats as described in any of the above.

[0050] <21> The alpha-linolenic acid content in the fatty acids that make up the oil is 40% by mass or more, For administering or applying to oils and fats containing acylglycerols of 25% by mass or more, flame Methods for the prevention, treatment, or improvement of symptomatic skin diseases. <22> Inflammatory skin diseases are preferably atopic dermatitis, seborrheic dermatitis, and contact dermatitis. Psoriasis, asteatotic eczema, erythema nodosum, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema Rash or dry skin, more preferably atopic dermatitis, seborrheic dermatitis, or contact dermatitis. , psoriasis, xerotic eczema, or erythema nodosum, and more preferably atopic dermatitis be <21> Method of description.

[0051] <23> The alpha-linolenic acid content in the fatty acids that make up the oil is 40% by mass or more, To administer or apply to oils and fats containing acylglycerols of 25% by mass or more, Methods for improving skin barrier function. <24> The skin barrier function is preferably a water permeability barrier function. <23> Method of description. <25> The alpha-linolenic acid content in the fatty acids that make up diacylglycerol is 40 by mass. % or more <21> ~ <24> One of the methods described above. [Examples]

[0052] Example 1 [Preparation of oils and fats and special feeds] Linseed oil (made by Archer Daniels Midland) is hydrolyzed using enzymes. The fatty acids obtained by disintegration were separated by cooling and centrifugation to obtain fractional fatty acids. Mix 300 parts by mass of fractionated fatty acids and 47 parts by mass of glycerin, and add commercially available immobilized 1,3-position selective ri The esterification reaction was carried out using Pase (Novozyme) as a catalyst. After filtering off the immobilized enzyme, The reaction product was subjected to molecular distillation, acid treatment, and water washing to obtain treated oil. After deodorizing the treated oil, antibacterial treatment was performed. By adding an oxidizing agent, linseed oil-derived diacylglycerol (DAG)-containing oil (lin-D AG) was prepared.

[0053] DAG oil (lin-DAG) and linseed oil (lin) prepared by the above method -TAG, manufactured by Summit Oil Co., Ltd.), and soybean oil (soy-TAG, manufactured by Nissin Oil Co., Ltd.) as a control. We prepared a (manufactured by Ilio Group Co., Ltd.) tag. In addition, lin-TAG and soy-TAG are also available. The same antioxidant as in lin-DAG was added at the same concentration. From AIN-93G (Oriental Yeast Co., Ltd.), which is used as mouse feed For the product from which the soybean oil (7% by mass) and corn starch (3% by mass) contained are removed. Three types of special feed were prepared by adding 10% by mass of any of the above-mentioned oils and fats. Glyceride composition and fatty acid composition of lin-DAG, lin-TAG, and soy-TAG It is shown in Table 1. The unsaturated fatty acid of C18:3 in the fatty acid composition of Table 1 is α-linolenic acid.

[0054] [Table 1]

[0055] The analysis methods for the glyceride composition and fatty acid composition are as follows. (i) Glyceride composition of fats and oils Approximately 10 mg of a fat and oil sample and 0.5 mL of a trimethylsilylating agent ("Silylating Agent TH", manufactured by Kanto Chemical Co., Inc.) were added to a glass sample bottle, sealed, and heated at 70 °C for 15 minutes. To this, 1.0 mL of water and 1.5 mL of hexane were added and shaken. After standing, the upper layer was subjected to gas chromatography (GLC) for analysis. [GLC analysis conditions] (Conditions) Apparatus: Agilent 6890 series (manufactured by Agilent Technologies) Integrator: ChemStation B 02.01 SR2 (manufactured by Agilent Technologies) Column: DB-1ht 10 m × 0.25 mm × 0.2 μm (manufactured by Agilent J&W) Carrier gas: 1.0 mL He / min Injector: Split (1:50), T = 340 °C Injection volume: 1 μL Detector: FID, T = 350 °C Oven temperature:升温 from 80 °C to 340 °C at 10 °C / min and hold for 15 minutes

[0056] (ii) Constituent fatty acid composition of fats and oils According to the "Method for Preparation of Fatty Acid Methyl Esters (2.4 .1.-1996)" in "Standard Oil Analysis Test Methods" edited by the Japanese Oil Chemists' Society, fatty acid methyl esters were prepared, and the obtained fat and oil sample was ​, American Oil Chemists. Society Official It was measured in accordance with Method Ce 1f-96 (GLC method). <GLC analysis conditions> Column: CP-SIL88 50m×0.25mm×0.2μm (VARIAN) Carrier gas: 1.0mL He / min Injector: Split(1:50), T = 300℃ Injection volume: 1μL Detector: FID, T = 300℃ Oven temperature: Hold at 150℃ for 5 min → Heat at 1℃ / min → Hold at 160℃ for 5 min → 2℃ / min heating → Hold at 200℃ for 10 min → Heat at 10℃ / min → Hold at 220℃ for 5 min

[0057] The fatty acids of diacylglycerol of lin-DAG, lin-TAG and soy-TAG The composition is shown in Table 2.

[0058]

Table 2

[0059] The analysis method of the fatty acid composition of diacylglycerol is as follows. After extracting and derivatizing the DAG fraction from each oil sample, it was subjected to gas chromatography -(GLC method) for analysis. At this time, the measurement method was in accordance with American Oil Chemists' Society (AOCS) Official Method Ce 1f-96. In addition, C18:3 in the fatty acid composition of Table 2 The unsaturated fatty acid is α-linolenic acid. <GLC analysis conditions> Equipment: Agilent 7890B (manufactured by Agilent Technologies) Column: CP-Sil 88 for FAME 50m x 0.25mm x 0. 2 μm (manufactured by Agilent Technologies) Carrier gas: 1.0 mL He / min Injector: Split (1:50), T=300℃ Injection volume: 1 μL Detector: FID, T=300℃ Oven temperature: Hold at 150°C for 5 minutes → Increase temperature by 1°C / min → Hold at 160°C for 5 minutes → Reduce temperature by 2°C Heat at 10°C / min → Hold at 200°C for 10 minutes → Heat at 10°C / min → Hold at 220°C for 5 minutes

[0060] [Exam Overview] (1) 32 NC / Nga male mice were subjected to a transcutaneous sensitization test, comparing an unsensitized group (soy-TAG(-) group) with a transcutaneous sensitized group. Groups of products (soy-TAG(+) group, lin-TAG(+) group, and lin-DAG(+) group) The mice were divided into four groups (N=8 in each group), and the mice in the percutaneous sensitization group were given the three types of special feeds mentioned above. Each group of mice was given free access to either of the following. The unsensitized group of mice was given soy-TAG-containing The mice were given a special diet free-feeding. After 30 days, the mice in the percutaneous sensitization group were given house dust mites. Biosta AD ointment (Biosta Co., Ltd.), containing the derived allergen, 100 mg, was administered to the neck of a mouse. It was applied uniformly to the back and auricle. Four days after the first application of Biosta AD, the mouse neck and back Distribute 150 μL of 4% by mass sodium dodecyl sulfate (SDS) aqueous solution evenly to the earlobe and auricle. Apply to the area once, and after the rough skin has softened, apply Biosta AD ointment 100mg again evenly to the same area. The ointment was applied. For the non-sensitized group of mice, Biosta AD ointment was not applied, and SDS aqueous solution was used. Only the liquid was applied. This procedure was repeated twice a week for a total of four times to treat atopic dermatitis. Inflammation was induced. 22 days after the initial application of Biosta AD ointment, mice were subjected to isoflurane inhalation. Under anesthesia, the animal was euthanized by cardiac blood sampling, and skin samples were taken from the neck and back, which are the sites where dermatitis is induced. The skin inflammation was visually observed before the initial application of Biosta AD ointment and 7, 14, and 21 days after application. Core evaluation, auricular thickness measurement, Tewameter™300 (Courag Transepidermal water loss (TEW) by e + Khazaka electronic GmbH Measurement of TEWL (Thoroughly Electrolyzed Wound), mRNA expression analysis of various cytokines in the skin at dermatitis-inducing sites. They did that.

[0061] The Dermatitis Score (AD score) was evaluated according to the indicators in Table 3 below. Each indicator: i) Redness ·Bleeding, (ii) eschar formation / dryness, (iii) edema, (iv) abrasion / tissue loss (4 items (0- The condition was evaluated on a scale of 3 points, and the sum of the resulting scores (0-12 points) was used as the final dermatitis score. .

[0062] [Table 3]

[0063] mRNA expression analysis in the skin at the site of dermatitis induction was performed as follows. Using the RNeasy Mini Kit (QIAGEN), skin samples were taken from the neck and back. Total RNA was extracted according to the recommended protocol. , SuperScript TM VILO TM cDNA Synthesis Kit (using Thermo Fisher Scientific) and following the recommended protocol cDNA was synthesized. Then, real-time PCR was performed using the obtained cDNA. This allows for the analysis of mRNA expression of various cytokines contained in the skin of the dermatitis-induced area. This was done. At this time, real-time PCR was performed using Taqman. TM Fast Uni versatile PCR Master Mix (2×) (Applied Biosys (tems) and each gene's specific Taqman TM Prepare the sample using a probe. Then, mRNA expression levels were detected. Ta was used in the expression analysis of various cytokine genes. qman TM The probes are shown in Table 4 below. RPLP0 is used as the endogenous control. I used it.

[0064] [Table 4]

[0065] (2) Results As shown in Figures 1, 2, and 3, compared to the non-sensitized soy-TAG(-) group, transdermal Soy-T cells were fed a special feed containing soy-TAG and lin-TAG from the sensitized group. In the AG(+) and lin-TAG(+) groups, dermatitis score, auricle thickening, and transfacial changes were observed. Although an increase in transepidermal water loss (TEWL) was observed, the animals were fed a special feed containing lin-DAG. In the lin-DAG(+) group, dermatitis score, auricle thickening, and TEWL were observed. All of these were significantly suppressed. Furthermore, as shown in Figure 4, in the skin of the dermatitis-inducing sites in the lin-DAG(+) group, Significant suppression of increased expression of IL-4, IL-1β, IL-6, TSLP, and IL-33 was confirmed. It was done. These cytokines are used in seborrheic dermatitis, contact dermatitis, psoriasis, xerotic eczema, and nodular dermatitis. Various inflammatory skin conditions such as erythema, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema, and dry skin. It has been reported to contribute to inflammatory responses and impaired barrier function in diseases. Therefore The oils and fats of this invention are effective against atopic dermatitis, seborrheic dermatitis, contact dermatitis, and psoriasis. xerotic eczema, erythema nodosum, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema, dry skin It can be said to be useful as a preventative, therapeutic, or ameliorative agent for various inflammatory skin diseases such as dry skin.

Claims

1. An agent for preventing, treating, or improving an inflammatory skin disease, comprising as an active ingredient an oil or fat, wherein the content of α-linolenic acid in the fatty acids constituting the entire oil or fat is 40% by mass or more, the content of diacylglycerol in the oil or fat is 60% by mass or more, and the content of α-linolenic acid in the fatty acids constituting the diacylglycerol is 40% by mass or more.

2. 2. The agent for preventing, treating or improving inflammatory skin diseases according to claim 1, wherein the inflammatory skin disease is atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, asteatotic eczema, erythema nodosum, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema or dry skin.

3. An agent for preventing, treating or improving inflammatory skin diseases as described in claim 1 or 2, wherein the content of alpha-linolenic acid in the fatty acids constituting the entire oil is 45% by mass or more, the content of diacylglycerol in the oil is 70% by mass or more, and the content of alpha-linolenic acid in the fatty acids constituting the diacylglycerol is 45% by mass or more.

4. An agent for preventing, treating or improving inflammatory skin diseases as described in claim 1 or 2, wherein the content of alpha-linolenic acid in the fatty acids constituting the entire oil and fat is 50% by mass or more, the content of diacylglycerol in the oil and fat is 80% by mass or more, and the content of alpha-linolenic acid in the fatty acids constituting the diacylglycerol is 50% by mass or more.

5. An agent for preventing, treating or improving inflammatory skin diseases as described in claim 1 or 2, wherein the triacylglycerol content in the oil or fat is 1% by mass or more and 25% by mass or less, and the monoacylglycerol content is 3% by mass or less.

6. An agent for preventing, treating or improving inflammatory skin diseases as described in claim 1 or 2, wherein the total content of saturated fatty acids among the fatty acids constituting the entire oil and fat is 0.5 mass% or more and 6.0 mass% or less.

7. A skin barrier function improving agent containing, as an active ingredient, an oil or fat in which the content of α-linolenic acid in the fatty acids constituting the entire oil or fat is 40% by mass or more, the content of diacylglycerol in the oil or fat is 60% by mass or more, and the content of α-linolenic acid in the fatty acids constituting the diacylglycerol is 40% by mass or more.

8. The skin barrier function improving agent according to claim 7, wherein the skin barrier function is a moisture permeation barrier function.

9. A food for preventing or improving inflammatory skin diseases, comprising as an active ingredient an oil or fat, the content of α-linolenic acid in the fatty acids constituting the entire oil or fat being 40% by mass or more, the content of diacylglycerol in the oil or fat being 60% by mass or more, and the content of α-linolenic acid in the fatty acids constituting the diacylglycerol being 40% by mass or more.

10. 10. The food for preventing or improving inflammatory skin diseases according to claim 9, wherein the inflammatory skin disease is atopic dermatitis, seborrheic dermatitis, contact dermatitis, psoriasis, asteatotic eczema, erythema nodosum, neonatal acne / acne-like rash, miliaria, folliculitis, infantile eczema or dry skin.

11. A food for improving skin barrier function contains as an active ingredient an oil or fat, in which the content of α-linolenic acid in the fatty acids constituting the entire oil or fat is 40% by mass or more, the content of diacylglycerol in the oil or fat is 60% by mass or more, and the content of α-linolenic acid in the fatty acids constituting the diacylglycerol is 40% by mass or more.

12. The food for improving skin barrier function according to claim 11, wherein the skin barrier function is a moisture permeation barrier function.

Images